The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease
Open accessAbstract
Diabetes is now a pandemic disease. Moreover, a large number of people with prediabetes are at risk for developing frank diabetes worldwide. Both type 1 and type 2 diabetes increase the risk of atherosclerotic cardiovascular disease (CVD). Even with statin treatment to lower LDL cholesterol, patients with diabetes have a high residual CVD risk. Factors mediating the residual risk are incompletely characterized. An attractive hypothesis is that remnant lipoprotein particles (RLPs), derived by lipolysis from VLDL and chylomicrons, contribute to this residual risk. RLPs constitute a heterogeneous population of lipoprotein particles, varying markedly in size and composition. Although a universally accepted definition is lacking, for the purpose of this review we define RLPs as postlipolytic partially triglyceride-depleted particles derived from chylomicrons and VLDL that are relatively enriched in cholesteryl esters and apolipoprotein (apo)E. RLPs derived from chylomicrons contain apoB48, while those derived from VLDL contain apoB100. Clarity as to the role of RLPs in CVD risk is hampered by lack of a widely accepted definition and a paucity of adequate methods for their accurate and precise quantification. New specific methods for RLP quantification would greatly improve our understanding of their biology and role in promoting atherosclerosis in diabetes and other disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“elevated plasma TG levels (with the accumulation of TRL and remnant particles) are related not only to subclinical atherosclerosis and vascular inflammation independently of LDL-C in statin-naïve, apparently healthy subjects”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At moderately elevated plasma TG levels, there is increased secretion of large TG-enriched VLDL and chylomicrons from the liver and small intestine that, when combined with suboptimal LpL action in obesity, insulin resistance, and/or diabetes mellitus, results in remnant accumulation.36”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The absence of lipolysis (i.e. complete LPL deficiency) results in the extreme elevation of large ‘nascent’ TRL without any concomitant increase in remnants;36,67,68 here, pancreatitis rather than ASCVD is the major risk.”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On a per particle basis, cholesterol-rich remnant particles are more potent inducers of macrophage foam cells than LDL and do not need structural modification to trigger uptake.36,93,141”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“but also equally to residual cardiovascular risk among statin-treated patients, especially those with diabetes mellitus.2,20,36–38”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
The Metabolic Basis of Inherited Disease
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-389_2 · Cited by 3,983
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 3×
“Furthermore, clinical trials of fibrates and n-3 fatty acids (polyunsaturated fatty acids, also often referred to as fish oils) have, with the exception of REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) and JELIS (Japan EPA Lipid Intervention Study), been mostly negative for CVD…”
BackgroundAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335 · cited 1×
“A recent new classification system of T2DM, based on different patient characteristics and risk of diabetes complications, divides adults into five different clusters of diabetes (3).”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 1×
“Abundant epidemiological evidence associated triglyceride levels with CVD risk (11,12), although the risk was often attenuated when adjusted for potential confounders, such as HDL-C (13).”
BackgroundTriglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Self-citationAtherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701 · cited 1×
“Despite decades of experimental data linking RLPs to atherogenesis in animal models and humans (70), the impact of RLPs as causal mediators in CVD associated with hypertriglyceridemia in patients with T2DM is still uncertain.”
BackgroundChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationPathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708 · cited 1×
“LDL-C concentrations are normal or only slightly elevated, but the LDL particles are characteristically small and dense with triglyceride enrichment (55).”
BackgroundPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“A key early observation was that a null mutation in APOC3, the gene encoding apoC-III (apoC3), which acts in part by inhibiting LPL, associated with reduced triglyceride levels and reduced CVD risk in an Amish population (15).”
Background
Research works printed but not linked: 1
- Mahley, 1989, Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 1195
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“Very low-density lipoproteins (VLDL), made in the liver, contain apoB100 and are metabolized to VLDL remnants, intermediate-density lipoproteins (IDL), and LDL. Chylomicrons, made in the intestine, are larger and contain apoB48, and are also metabolized to remnant particles but not to IDL and LDL ( Figure 1 ).”
BackgroundInfluentialSelf-citationThe Role of Inflammation in Cardiovascular Disease
Henein, M. Y., Vancheri, S., Longo, G., & Vancheri, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112906 · Cited by 724
2023 Chinese guideline for lipid management
Li, J.-J., Zhao, S.-P., Zhao, D., Lu, G.-P., Peng, D.-Q., Liu, J., Chen, Z.-Y., Guo, Y.-L., Wu, N.-Q., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 223
Management of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 223
Cardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K. E., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 212
Self-citationNon-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook
Raja, V., Aguiar, C., Alsayed, N., Chibber, Y. S., ElBadawi, H., Ezhov, M., Hermans, M. P., Pandey, R. C., Ray, K. K., Tokgözoglu, L., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117312 · Cited by 196
Lipid and Lipoprotein Metabolism
Feingold, K. R. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.008 · Cited by 197
Addressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
“Cholesterol-rich remnant particles carry a bigger load of cholesterol, are more effective at inducing macrophage foam cells than LDL, and do not need to be modified by oxidation in order to be taken up by macrophages (18).”
BackgroundSelf-citationRemnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk
Burnett, J. R., Hooper, A. J., & Hegele, R. A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.029 · Cited by 135
Zhao, Y., Zhuang, Z., Li, Y., Xiao, W., Song, Z., Huang, N., Wang, W., Dong, X., Jia, J., Clarke, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46686-x · Cited by 117
“This needs to be mentioned in the Discussion section.”
Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease
Duran, E. K., & Pradhan, A. D. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa296 · Cited by 120
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 128
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 118
Chen, J., Wu, Q., Liu, H., Hu, W., Zhu, J., Ji, Z., & Yin, J. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.015 · Cited by 116
“When RC infiltrates the arterial wall, it can accumulate in the intima, causing endothelial dysfunction and initiating vascular inflammation and cholesterol deposition [18,19].”
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2023) · Diabetologia · doi:10.1007/s00125-023-06016-0 · Cited by 98
“…levels, probably as a result of both increased production of triglyceride-rich lipoproteins due to dietary and lifestyle factors, and increased retention of triglyceride-rich lipoproteins in plasma due to insulin resistance and hyperglycaemia, which inhibit lipoprotein lipase activity [8, 15].”
BackgroundInfluentialRemnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes
Sigfrids, F. J., Dahlström, E. H., Forsblom, C. M., Sandholm, N., Harjutsalo, V., Taskinen, M., & Groop, P. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13298 · Cited by 92
Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis
Qiu, M., Zhou, X., Zippi, M., Goyal, H., Basharat, Z., Jagielski, M., & Hong, W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2265939 · Cited by 101
“Residual lipoproteins, absorbed by the vascular endothelium, are able to promote inflammation and atherosclerosis through various mechanisms, including abnormal secretion by endothelial cells and reduced flow-mediated dilatation [37].”
BackgroundTriglycerides and cardiovascular disease
Esan, O., & Wierzbicki, A. S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000862 · Cited by 92
Lipids dysregulation in diseases: core concepts, targets and treatment strategies
Dakal, T. C., Xiao, F., Bhusal, C. K., Sabapathy, P. C., Segal, R., Chen, J., & Bai, X. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02425-1 · Cited by 104
“Beyond LDL cholesterol, other apolipoprotein B-containing lipoproteins, like lipoprotein(a) (Lp(a)) and triglyceride-rich lipoproteins, also contribute to cardiovascular risk [90].”
Triglyceride-rich lipoproteins and cardiovascular diseases
Xu, D., Xie, L., Cheng, C., Xue, F., & Sun, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1409653 · Cited by 73
Hypertriglyceridemia—causes, significance, and approaches to therapy
Santos-Baez, L. S., & Ginsberg, H. N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00616 · Cited by 66
“that which is converted to LDL ranges from 25 to 75%; regulation of the path that a VLDL particle takes is not understood completely, although LpL activity appears to play a critical role (10, 11).”
BackgroundSelf-citationDyslipidemia in Pediatric Type 2 Diabetes Mellitus
Sunil, B., & Ashraf, A. P. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01336-6 · Cited by 79
“Despite the milieu of IR, the liver remains sensitive to the effect of insulin on net lipid synthesis [7].”
BackgroundHuang, H., Guo, Y., Liu, Z., Zeng, Y., Chen, Y., & Xu, C. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac283 · Cited by 69
Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
Gugliucci, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134399 · Cited by 74
New Therapies for Lowering Triglyceride-Rich Lipoproteins
Rosenson, R. S., Shaik, A., & Song, W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.051 · Cited by 72
Kim, H., Lim, D. H., & Kim, Y. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18115597 · Cited by 69
“Concurrent obesity and elevated glucose levels can accelerate abnormal lipid metabolism in individuals with T2DM [11,12].”
BackgroundPackard, C. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00994-z · Cited by 57
Intestinal lipid absorption and transport in type 2 diabetes
Vergès, B. L. (2022) · Diabetologia · doi:10.1007/s00125-022-05765-8 · Cited by 64
Basu, D., & Bornfeldt, K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00504 · Cited by 52
“New tools and methods to measure and evaluate TRLs and RLPs will also be critical for understanding if TRLs and RLPs have distinct effects on atherosclerotic lesions and as risk factors for CVD (23).”
BackgroundMethodSelf-citationInflammatory Links Between Hypertriglyceridemia and Atherogenesis
Peng, X., & Wu, H. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01006-w · Cited by 53
Chait, A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.010 · Cited by 58
Self-citationHsu, C.-C., Fidler, T. P., Kanter, J. E., Kothari, V. M., Kramer, F., Tang, J., Tall, A. R., & Bornfeldt, K. (2023) · Diabetes · doi:10.2337/db22-0962 · Cited by 50
Self-citationGao, S., Xu, H., Ma, W., Yuan, J., & Yu, M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024366 · Cited by 53
“17 The proathero-genic effect of RC has been confirmed, 20,21 which may involve proinflammatory responses, oxidative stress, platelet aggregation, endothelial dysfunction, foam cell formation, and smooth muscle cell proliferation.”
Apolipoprotein C3: form begets function
Bornfeldt, K. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100475 · Cited by 54
“Remnant lipoprotein particles can be defined as postlipolytic partially triglyceride-depleted particles derived from chylomi-crons and very-low-density lipoprotein (VLDL) that are relatively enriched in cholesteryl esters and apolipoprotein E (APOE) (5).”
BackgroundMethodInfluentialSelf-citationDing, X., Tian, J., Chang, X., Liu, J., & Wang, G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf248 · Cited by 46
Targeting the vasculature in cardiometabolic disease
Boutagy, N. E., Singh, A. K., & Sessa, W. C. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148556 · Cited by 46
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease
Ganda, O. P. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000875 · Cited by 46
The chylomicron saga: time to focus on postprandial metabolism
Gugliucci, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1322869 · Cited by 55
“As we illustrate in Figure 7, one important factor raising the risk of ASCVD is the capacity of cholesterol-enriched residual lipoproteins to transfer their lipid cargo to macrophages, which are the cells responsible for cholesterol deposition in arterial plaques (25, 31, 104).”
BackgroundGenetics of hypertriglyceridemia and atherosclerosis
Gill, P. K., Dron, J. S., & Hegele, R. A. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000839 · Cited by 41
Quartet of APOCs and the Different Roles They Play in Diabetes
Hsu, C.-C., Kanter, J. E., Kothari, V. M., & Bornfeldt, K. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318290 · Cited by 41
Self-citationHypertriglyceridaemia: an update
Wierzbicki, A. S., Kim, E. J., Esan, O., & Ramachandran, R. (2022) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207719 · Cited by 51
Calcaterra, I. L., Lupoli, R., Minno, A. D., & Minno, M. N. D. D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13841 · Cited by 41
Zhu, Y., Wei, Y., Karras, I., Cai, P.-J., Xiao, Y., Jia, C., Qian, X.-L., Zhu, S.-Y., Zheng, L.-J., Hu, X., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.913729 · Cited by 42
NAFLD: An Emerging Causal Factor for Cardiovascular Disease
Li, M., Wang, H., Zhang, X., Cai, J., & Li, H. (2023) · Physiology · doi:10.1152/physiol.00013.2023 · Cited by 49
Intermittent Fasting Regulates Metabolic Homeostasis and Improves Cardiovascular Health
Diab, R., Dimachkie, L., Zein, O., Dakroub, A. H., & Eid, A. H. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01314-9 · Cited by 50
“When VLDL reaches target organs, TG are taken up via lipoprotein lipase (LPL) [13].”
BackgroundKowalska, K., Sabatowska, Z., Forycka, J., Młynarska, E., Franczyk, B., & Rysz, J. (2022) · Biomedicines · doi:10.3390/biomedicines10092320 · Cited by 38
“Like the LDL particles, TRLs can be taken up by macrophages present in the arterial wall, and therefore contribute to the inflammatory process [69,70].”
BackgroundLipid management for cardiovascular risk reduction in type 1 diabetes
Tell, S., Nadeau, K. J., & Eckel, R. H. (2020) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000551 · Cited by 30
“However, the relationship between hypertriglyceridemia and CVD is likely only an association as atherosclerotic plaque primarily contains cholesteryl ester derived from cholesterol-rich lipoprotein remnants of triglyceriderich lipoproteins (such as very-low-density lipoproteins and chylomicrons), rather than triglycer…”
BackgroundTaskinen, M., Björnson, E., Kahri, J., Söderlund, S., Matikainen, N., Porthan, K., Ainola, M., Hakkarainen, A., Lundbom, N. M. I., Fermanelli, V., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315446 · Cited by 33
“However, it is noteworthy that (1) statins have a more marked effect than evolocumab on plasma triglyceride and total VLDL-apoB100 FCR,52 (2) we previously found statin therapy to have a significant impact on VLDL1 metabolism, 57 and (3) in subjects with homozygous familial hypercholesterolemia (who lack LDL receptors…”
BackgroundMethodInfluentialLipid effects of glucagon-like peptide 1 receptor analogs
Berberich, A. J., & Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000750 · Cited by 32
“All rights rese increased TG-rich remnant particles, also appear to play a role in atherogenesis and have been independently associated with worse cardiovascular outcomes [8,9].”
BackgroundTaskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J. T., Ainola, M., Hakkarainen, A., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160607 · Cited by 31
“The net effect of genetically determined lower apoC-III on ASCVD risk is well documented; however, how this is linked to the substantial perturbations in TRL metabolism given that LDL levels are not altered is yet to be defined.”
BackgroundInfluentialGoldberg, R. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.011 · Cited by 34
Li, B., Liu, Y., Zhou, X. J., Chen, L., Yan, L., Tang, X., Gao, Z., Wan, Q., Luo, Z., Qin, G., et al. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13592 · Cited by 33
“55 TG is readily metabolized in most cells, while cholesterol is not easily broken down, so it is RC, not TG, that is the deleterious component of TGRL. 56 Actually, TG might simply be a clinical surrogate for TGRL or RC, but they stand for different disorders of lipids, with RC being cholesterol…”
BackgroundSkudder‐Hill, L., Sequeira, I. R., Ko, J., Cho, J., Poppitt, S. D., & Petrov, M. S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15233 · Cited by 29
Keeping remnants in perspective
Borén, J., & Packard, C. J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab531 · Cited by 26
“Several different approaches have been used to date including sequential ultracentrifugation, immunoaffinity assays, nuclear magnetic resonance (NMR) spectroscopy, calculations based on cholesterol measurements in various lipoprotein classes, or simply dividing plasma triglyceride concentration by a factor.(6) Assessm…”
MethodWharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02781-x · Cited by 26
“These changes may be prognostically important, as the relationships of cardio-vascular risk with these apolipoproteins are additive to the risk associated with traditional lipid species [18].”
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 29
Self-citationYanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073418 · Cited by 27
“Approximately 25–75% of VLDL remnants are not uptaken by the liver, but rather are rather changed to LDL [19].”
BackgroundMonocyte and macrophage foam cells in diabetes-accelerated atherosclerosis
Cervantes, J., & Kanter, J. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1213177 · Cited by 27
“Insulin also significantly affects lipid metabolism, and people with less wellcontrolled type 1 diabetes or type 2 diabetes often have elevated levels of triglyceride-rich lipoproteins (VLDL and chylomicrons) and their partially metabolized remnants, which are believed to be highly atherogenic (14).”
BackgroundNonalcohol fatty liver disease: balancing supply and utilization of triglycerides
Santos‐Báez, L. S., & Ginsberg, H. N. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000756 · Cited by 26
Self-citationKropp, M., Clerck, E. E. B. D., Vo, T.-T. K. S., Thumann, G., Costigliola, V., & Golubnitschaja, O. (2023) · The EPMA Journal · doi:10.1007/s13167-023-00318-4 · Cited by 27
Shimizu‐Albergine, M., Basu, D., Kanter, J. E., Kramer, F., Kothari, V., Barnhart, S., Thornock, C., Mullick, A. E., Clouet-Foraison, N., Vaisar, T., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153285 · Cited by 26
“Remnant lipoproteins are highly atherogenic, as evidenced by the increased cardiovascular disease (CVD) risk in individuals with remnant removal disease (also known as familial dysbetalipoproteinemia or type III hyperlipoproteinemia) (16-19).”
BackgroundMethodSelf-citationMangalesh, S., Yadav, P., Dudani, S., & Mahesh, N. K. (2022) · Coronary Artery Disease · doi:10.1097/mca.0000000000001166 · Cited by 27
Taskinen, M., Matikainen, N., Björnson, E., Söderlund, S., Inkeri, J., Hakkarainen, A., Parviainen, H., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06008-0 · Cited by 25
“Elevated plasma concentrations of chylomicrons and VLDL, particularly their partial lipolysis products—rem-nants and intermediate-density lipoproteins (IDLs)—have been associated with increased ASCVD risk in epidemiological studies and clinical trials [14, 17–19].”
BackgroundThe Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease
Bornfeldt, K. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317163 · Cited by 23
Self-citationMasuda, R., Wist, J., Lodge, S., Kimhofer, T., Hunter, M. L., Hui, J., Beilby, J. P., Burnett, J. R., Dwivedi, G., Schlaich, M. P., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.06.004 · Cited by 23
Vargas‐Vázquez, A., Fermín‐Martínez, C. A., Antonio‐Villa, N. E., Fernández‐Chirino, L., Ramírez‐García, D., Dávila-López, G., Díaz-Sánchez, J. P., Aguilar-Salinas, C. A., Seiglie, J. A., & Bello‐Chavolla, O. Y. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117508 · Cited by 23
Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
Burks, K. H., Stitziel, N. O., & Davidson, N. O. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101409 · Cited by 27
Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis
Miura, Y., & Suzuki, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416224 · Cited by 22
“Increases in TRL remnants are accentuated in insulin-resistant states [56].”
BackgroundRemnant Cholesterol: The Leftovers and Their Contribution to Atherosclerotic Cardiovascular Disease
Bruemmer, D., & Cho, L. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.121.012615 · Cited by 21
Jang, S. Y., Kang, M., Song, E., Jang, A., Choi, K. M., Baik, S. H., & Yoo, H. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111639 · Cited by 20
Shui, X., Chen, Z., Wen, Z., Tang, L., Tang, W., Liao, Y., Wu, Z., & Chen, L. (2022) · Angiology · doi:10.1177/00033197221080911 · Cited by 22
Sugar and Dyslipidemia: A Double-Hit, Perfect Storm
Gugliucci, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175660 · Cited by 19
Yang, J., Wang, Y., Xi, Z., Ma, Y., Shao, C., Wang, W., & Tang, Y. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120452 · Cited by 19
“In that case, the TRLs may play an important role in the cardiovascular residual risk, especially for patients with metabolic disorders, such as diabetes mellitus, metabolic syndrome, and insulin resistance [13,27].”
BackgroundHeo, J. H., Jung, H. N., Roh, E., Han, K., Kang, J. G., Lee, S. J., & Ihm, S. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00112-0 · Cited by 16
Shao, Y., Li, Z., Sun, M., Wu, Q., Shi, H., & Ye, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16383 · Cited by 19
Jang, S.-J., Tuan, W.-L., Hsu, L., Er, L., Teng, M., Wu, S., & Ko, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314963 · Cited by 16
“Non-HDL and remnant cholesterol levels were calculated as total cholesterol minus HDL cholesterol levels and total cholesterol minus HDL cholesterol minus LDL cholesterol, respectively [56].”
BackgroundLi, B., Zhou, X. J., Wang, W., Gao, Z., Yan, L., Qin, G., Tang, X., Wan, Q., Chen, L., Luo, Z., et al. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13362 · Cited by 17
“On the other hand, increased RC concentrations have been reported to lead to atherosclerosis risk even in individuals with normal TG levels.(35) As our results show, even if TG levels are appropriate, elevated RC and the corresponding risk of diabetes could not be ignored.”
BackgroundColesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve, V., Millán, J., Blanco, A., Blasco, M., Díaz-Díaz, J. L., Rodríguez, Á. D., Mangas, A., Pascual, V., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.02.001 · Cited by 28
Zhu, W., Liu, Q., Liu, F., Jiao, C., Zhang, L., & Xie, H. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02249-6 · Cited by 17
“Several studies suggest that the RC produced by very low-density lipoprotein and chylomicron lipolysis contributes to this residual risk [28].”
BackgroundRisk factors for cardiovascular diseases in patients with vitiligo: an analysis of current evidence
Liang, X., Guo, F., Zhang, M., Wang, C., Lin, N., Liu, L., Chen, Y., Liu, F., Du, Y., Li, L., et al. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2326297 · Cited by 15
Modeling cholesterol metabolism and atherosclerosis
Auley, M. T. M. (2021) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1546 · Cited by 17
Chen, S., Xu, Y., Chen, B., Lin, S., Lu, L., Cheng, M., Wang, Y., Yang, Q., Ling, S., Zhou, D., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02064-6 · Cited by 16
“TGs in TRLs are hydrolyzed in the circulation, generating residual particles rich in cholesterol esters, the cholesterol part of which is called RC [41].”
BackgroundTeng, M., Yeh, K.-H., Hsu, L., Chou, H., Er, L., Wu, S., & Ko, Y. (2023) · Genes · doi:10.3390/genes14030754 · Cited by 14
“Non-HDL and remnant cholesterol levels were calculated by subtracting HDL from total cholesterol levels and by subtracting HDL and LDL from total cholesterol levels, respectively [45].”
MethodWeaver, O. R., Krysa, J. A., Ye, M., Vena, J. E., Eurich, D. T., & Proctor, S. D. (2023) · CMAJ Open · doi:10.9778/cmajo.20210318 · Cited by 14
“23 These results also align with studies in humans and rodent models with dyslipidemia showing that statins, which reduce cholesterol synthesis in the liver, may also induce an upregulation of absorption and secretion of cholesterol in the intestine.”
Huang, K., Yin, S., Xiao, Y., Wang, J., Cui, J., Wang, J., & Bai, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02046-8 · Cited by 18
“However , the causal connection between RC and ED necessitates additional research.”
BackgroundPancreatic and cardiometabolic complications of severe hypertriglyceridaemia
Bashir, B., Ferdousi, M., Durrington, P. N., & Soran, H. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000939 · Cited by 14
Colesevelam – a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia
Esan, O., Viljoen, A., & Wierzbicki, A. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2112945 · Cited by 14
“contribution of triglyceride (TG)-rich lipoproteins; (TGRLs) [3,4] to”
BackgroundRosenson, R. S., Rader, D. J., Ali, S., Banerjee, P., McGinniss, J., & Pordy, R. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07567-z · Cited by 13
Li, B., Zhou, X. J., Liu, Y., Zhang, Y., & Mu, Y. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64146 · Cited by 12
“In addition, high RC has been reported to contribute to the risk of atherosclerosis even in populations with normal TG levels 51) .”
BackgroundChen, Z., Wang, S., Pottekat, A., Duffey, A., Jang, I., Chang, B. H., Cho, J., Finck, B. N., Davidson, N. O., & Kaufman, R. J. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101874 · Cited by 13
“Overproduction of hepatic VLDL is a common cause of hyperlipidemia in obesity and type II diabetes [2,4 e 7].”
BackgroundRazavi, A. C., Bazzano, L., He, J., Krousel-Wood, M. A., DORANS, K. S., Razavi, M. A., Fernandez, C., Whelton, S. P., & Kelly, T. N. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100190 · Cited by 12
Liu, T., Zhao, D., Wang, M., Sun, J., Liu, J., Li, J., Duan, Y., Hu, P., Sun, Z., Liu, J., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63937 · Cited by 11
A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Wang, L., Zhang, Q., Wu, Z., & Huang, X. (2024) · Medicine · doi:10.1097/md.0000000000038754 · Cited by 17
“Furthermore, owing to their extended residence within the vessel wall, remnants are considered to possess an atherogenic potential comparable to that of LDL-C [12–14] (Fig.”
BackgroundMills, C. E., Harding, S., Bapir, M., Mandalari, G., Salt, L. J., Gray, R., Fielding, B. A., Wilde, P. J., Hall, W. L., & Berry, S. E. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa413 · Cited by 11
Remnant cholesterol, vascular risk, and prevention of atherosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve-Luque, V., & Millán, J. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.005 · Cited by 18
Luo, Y., Cui, S., Zhang, C., Huang, R., Zhao, J., Su, K., Luo, D., & Li, Y. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s348148 · Cited by 12
Research advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 15
Ozcariz, E., Guardiola, M., Amigó, N., Rojo‐Martínez, G., Valdés, S., Rehues, P., Masana, L., & Ribalta, J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110772 · Cited by 10
Hansen, M. K., Mortensen, M. B., Olesen, K. K. W., Thrane, P. G., Thomsen, R. W., & Mæng, M. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae119 · Cited by 12
Li, W., Liu, Y., Liu, J., Guo, Q., Li, J., Wang, A., & Zheng, H. (2024) · Stroke and Vascular Neurology · doi:10.1136/svn-2023-002888 · Cited by 12
“In the future, not only in primary and secondary prevention but also in related studies, we should put more focus on lowering RC concentration to avoid clinical events such as ischaemic stroke and myocardial infarction and their recurrence.”
Background
Metadata
- Authors
- Chait, A., Ginsberg, H. N., Vaisar, T., Heinecke, J. W., Goldberg, I. J., & Bornfeldt, K. E.
- Affiliations
- University of Washington (US)
- Columbia University (US)
- Department of Medicine, University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA
- New York University (US)
- Corresponding author
- Bornfeldt, Karin E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-03-16
- Volume
- 69
- Issue
- 4
- Pages
- 508-516
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC7085249
- OpenAlex
- W3011963422
- Cited by
- 229
- References
- 72
- Citations by year
- 2026: 26 · 2025: 36 · 2024: 49 · 2023: 46 · 2022: 38 · 2021: 21 · 2020: 13
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL126028, R01HL127694, P01HL092969, R01HL45095, R01HL73029, P01HL128203, R01HL144558, R35HL135833)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK017047, DP3DK108209)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- remnant lipoproteins, triglyceride-rich lipoproteins, atherosclerotic cardiovascular disease, residual cardiovascular risk, prediabetes, apolipoprotein E, apolipoprotein B-48, apolipoprotein B-100, chylomicrons, VLDL, lipolysis, atherosclerosis
- MeSH terms
- Animals, Cardiovascular Diseases, Chylomicrons, Diabetes Mellitus, Type 2, Humans, Lipoproteins, Lipoproteins, VLDL, Triglycerides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.